ARCE Tx to Advance ARD103 into the Clinic after Promising Preclinical Results in AML; NKGen Biotech and Affimed not Proceeding to Ph2 Trial Combining AFM24 and SNK01 in Solid Tumors; ASCO Breakthrough 2023 Analysis
ASCO Breakthrough 2023 Analysis: ARCE Tx reported preclinical updates from ARD103, a CLL-1 CAR-T manufactured with its DashCAR technology, while NKGen biotech and Affimed presented initial results of their collaboration to evaluate SNK01 (autologous NK cells) in combination with AFM24 (EGFR x CD16 bispecific NK cell engager) in advanced or metastatic EGFR+ solid tumors.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.